Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan and Simvastatin Combination in Hypertension and Dyslipidemia
NCT00316095Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2006
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of telmisartan and simvastatin in hypertension (HTN) and hypercholesterolemia (8 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Change in 24-hour ambulatory blood pressure measurement (ABPM) measured mean diastolic blood pressure (DBP) at 8 weeks and Change in low density lipoprotein (LDL) at 8 weeks. Started Apr 2006; status: completed.
02
Drugs
telmisartansimvastatin
03
Conditions
hypertension (HTN)hypercholesterolemia
Beyond the preview
Go deeper on NCT00316095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00316095.